Transfusion-dependent thalassemia Market to Grow at a Substantial Growth Rate During the Forecast Period 2032 - DelveInsight



The Transfusion-dependent thalassaemia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Transfusion-dependent thalassaemia pipeline products will significantly revolutionize the Transfusion-dependent thalassaemia market dynamics. 

DelveInsight’s “Transfusion-dependent thalassaemia Market Insights, Epidemiology, and Market Forecast-2032″ report offer an in-depth understanding of the Transfusion-dependent thalassaemia, historical and forecasted epidemiology as well as the Transfusion-dependent thalassaemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. 

Some of the key facts of the Transfusion-dependent thalassaemia Market Report: 

  • The Transfusion-dependent thalassaemia market size is anticipated to grow with a significant CAGR during the study period (2019-2032)  

  • Secondary iron overload is the main issue with Transfusion-dependent thalassaemia; if handled, it can cause damage to target organs and even death 

  • Transfusion-dependent thalassaemia prevalence is rare in the United States 

  • The prevalence of symptomatic cases of Transfusion-dependent thalassaemia estimates to be approximately 1 in 100,000 individuals in the general population 

  • Key Transfusion-dependent thalassaemia Companies: Celgene, bluebird bio, Sangamo Therapeutics, Protagonist Therapeutics, Novartis Pharmaceuticals, Vertex Pharmaceuticals, and others 

  • Key Transfusion-dependent thalassaemia Therapies: PTG-300, BIVV003, Mitapivat, Deferasirox, Luspatercept, sofosbuvir/velpatasvir, Deferasirox dispersable tablet, and others 

  • Transfusion dependence happens when a patient needs an average of more than 2 units of blood transfused every 28 days for at least three months

Request a sample for the Transfusion-dependent thalassaemia Market Report 

Transfusion-dependent thalassaemia Overview

According to the severity of the phenotype, which is brought on by a wide range of mutations in a homozygous or compound heterozygous state, -thalassemias can be categorised clinically as transfusion-dependent thalassemia (TDT) and non-transfusion-dependent thalassemia (NTDT).

Reduced synthesis of the -globin chain, which causes a /-chain imbalance, the precipitation of -globin-heme complexes, and poor erythropoiesis are the hallmarks of -thalassemias. The disease's hallmarks—ineffective erythropoiesis, persistent hemolytic anaemia, and compensatory hematopoietic expansion—are connected to how severe the chain unbalance is. Numerous clinical variants of beta-thalassemia, such as haemoglobin E/beta-thalassemia, which results from beta-thalassemia coinheritance with haemoglobin E, have been reported. 

Transfusion-dependent thalassaemia Symptoms  

The Transfusion-dependent thalassaemia symptoms include -

  • Body Fatigue

  • Weakness

  • Shortness of breathing

  • Dizziness

  • Headaches

  • Nausea and vomiting

Discover more about therapies set to grab major Transfusion-dependent thalassaemia market share @ Transfusion-dependent thalassaemia market forecast 

Transfusion-dependent thalassaemia Epidemiology Segmentation:

The Transfusion-dependent thalassaemia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Transfusion-dependent thalassaemia

  • Prevalent Cases of Transfusion-dependent thalassaemia by severity

  • Gender-specific Prevalence of Transfusion-dependent thalassaemia

  • Diagnosed Cases of Episodic and Chronic Transfusion-dependent thalassaemia 

Transfusion-dependent thalassaemia Market  

The dynamics of the Transfusion-dependent thalassaemia market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as Mitapivat, Deferasirox, and others during the forecasted period 2019-2032.

Download the report to understand which factors are driving Transfusion-dependent thalassaemia epidemiology trends @ Transfusion-dependent thalassaemia Epidemiological Insights

Transfusion-dependent thalassaemia Therapies

  • PTG-300

  • BIVV003

  • Mitapivat 

  • Deferasirox

  • Luspatercept

  • sofosbuvir/velpatasvir

  • Deferasirox dispersable tablet

Transfusion-dependent thalassaemia Key Companies 

  • Celgene

  • bluebird bio

  • Sangamo Therapeutics 

  • Protagonist Therapeutics

  • Novartis Pharmaceuticals 

  • Vertex Pharmaceuticals 

Scope of the Transfusion-dependent thalassaemia Market Report

  • Study Period: 2019–2032

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Transfusion-dependent thalassaemia Companies: Celgene, bluebird bio, Sangamo Therapeutics, Protagonist Therapeutics, Novartis Pharmaceuticals, Vertex Pharmaceuticals, and others

  • Key Transfusion-dependent thalassaemia Therapies: PTG-300, BIVV003, Mitapivat, Deferasirox, Luspatercept, sofosbuvir/velpatasvir, Deferasirox dispersable tablet, and others

  • Therapeutic Assessment: Transfusion-dependent thalassaemia current marketed and Transfusion-dependent thalassaemia emerging therapies

  • Migraine Market Dynamics:  Transfusion-dependent thalassaemia market drivers and barriers 

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Unmet Needs, KOL’s views, Analyst’s views, Transfusion-dependent thalassaemia  Market Access and Reimbursement 

To know more about Transfusion-dependent thalassaemia treatment, visit @ Transfusion-dependent thalassaemia Medications 

Related Reports:  

 

Diagnostic Imaging Equipment Market

 

Diagnostic Imaging Equipment Market By Product (X-Ray Imaging Systems, Computed Tomography (CT) Scanners, Ultrasound Systems, Magnetic Resonance Imaging (MRI) Systems, Nuclear Imaging Systems, Mammography Systems, And Others), By Application (Cardiology, Oncology, Gastroenterology, Gynecology, And Other Applications), By End-User (Hospitals, Diagnostic Imaging Centres, And Others), by geography is expected to grow at a steady CAGR forecast till 2026 owing to rising technological advancement and increasing prevalence of chronic diseases.

 

Invasive Candidiasis Market

 

"DelveInsight’s ‘Invasive Candidiasis Market Insight, Competitive Landscape and Market Forecast, 2027’ report delivers an in-depth understanding of Invasive Candidiasis and the historical and forecasted Invasive Candidiasis market trends, globally, which comprises of North America, Europe, APAC, and RoW.

 

Sialidosis Market 

 

DelveInsight's "Sialidosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Sialidosis, historical and forecasted epidemiology as well as the Sialidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Filgrastim Biosimilar Insight

 

DelveInsight’s, “Filgrastim Biosimilar Insight, 2022,” report provides comprehensive insights about 20+ companies and 20+ marketed and pipeline drugs in the Filgrastim Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

 

Pain Management Devices Market

 

Pain Management Devices Market By Type Of Devices (Neuromodulation & Neurostimulation Devices, Analgesic Infusion Pumps [Intrathecal Infusion Pumps and External Infusion Pumps], Ablation Devices [Radiofrequency Ablation Devices And Cryoablation Devices], And Others), By Application (Neuropathic Pain, Cancer Pain, Facial & Migraine Pain, Musculoskeletal Pain, and Others), By Geography is expected to grow at a steady CAGR Forecast till 2027 

Latest Reports by DelveInsight

Basal Cell Carcinoma Market | Birch Allergy Market | Bile Duct Neoplasm Market | Gingivitis Market |  Lupus Nephritis Market | Severe Hypertriglyceridemia (SHTG) Market | Arthralgia Market | Severe Hypertriglyceridemia (SHTG) Market | Arthralgia Market | Congestive Heart Failure Market | Gingivitis Market | Lupus Nephritis Market | Erythromelalgia Market | AL Amyloidosis Market | Primordial Dwarfism Market | Breast Pumps Market | Hyperuricemia Market | Helicobacter Pylori (H. pylori) Infection Market | AIDS Dementia- Market | Follicular Lymphoma Market | Chronic Pulmonary Hypertension Market | Adrenal Crisis Market | Retinoblastoma Market | Non-Cystic Fibrosis Bronchiectasis Market | Microsatellite Stable Colorectal Cancer Market | Chondrosarcoma Market | Sialidosis Market


To know more about our Competitive Services, Click here: Pharma Competitive Intelligence

https://www.delveinsight.com/consulting/competitive-intelligence-services

Comments

Post a Comment

Popular posts from this blog

Eli Lilly’s Donanemab: The FDA’s Latest Approval in Alzheimer’s Disease Treatment

Image
  The Birth of a Breakthrough Eli Lilly’s groundbreaking drug, Donanemab, has recently received FDA approval, marking a significant milestone in Alzheimer’s disease treatment . This innovative therapy, designed to target and reduce amyloid plaques in the brain, offers new hope for patients battling this debilitating condition. Donanemab’s approval comes at a pivotal moment, as it represents a major advancement in the Alzheimer’s disease pipeline, promising improved outcomes for those affected. Navigating Regulatory Waters The journey of Donanemab through the regulatory landscape was complex, characterized by rigorous scrutiny and extensive clinical trials. Eli Lilly’s success in obtaining FDA approval highlights the drug’s potential to revolutionize Alzheimer’s disease therapies . This regulatory endorsement not only underscores the efficacy and safety of Donanemab but also sets a new standard for the evaluation of future treatments. Donanemab: Cost and Coverage As with many groundbre
Read more

CELMoDs and the Future of Multiple Myeloma Treatment

Image
  What is Multiple myeloma and How is it to be treated? Multiple myeloma is a cancer of plasma cells, and it affects approximately 138,000 people worldwide. The multiple myeloma market is dominated by several drugs, with REVLIMID being the leading therapy. However, with the entry of CELMoDs , such as iberdomide, many believe that they could be a worthy successor to REVLIMID. Generic competition to REVLIMID REVLIMID, also known as lenalidomide, is one of the most widely prescribed drugs for multiple myeloma . However, the drug has faced significant competition in recent years, with the entry of generic versions in 2022. The introduction of generic REVLIMID has had a considerable impact on the multiple myeloma market , with many patients switching to cheaper alternatives. The arrival of CELMODS CELMoDs, or cereblon modulating drugs, are a new class of drugs that work in a similar way to REVLIMID. They are designed to modify the activity of cereblon, a protein that plays a crucial role
Read more

Analyzing the Benefits of Medical Coding in Enhancing Healthcare Quality and Safety

Image
The healthcare business has experienced tremendous growth and development over the past few decades due to technological advancements, which have also greatly streamlined the patient treatment process. The development of cutting-edge targeted medicines, inventive procedures, and inventive medical equipment has improved medical function and raised the standard of healthcare services. Akin to accounting, medical coding is a hidden sector of the healthcare sector that is little understood by the general public but is crucial to enhancing patient care. The process of medical billing and coding begins with medical coding. It is a very intricate and constantly changing field that is used to identify and organise medical services, diagnoses, and procedures. The practise of gathering and sharing crucial data about clinical procedures and services in a patient's records is known as medical billing and coding. It enables a precise method of describing patient care, which further facilitates
Read more